Keywords: Chromosome, aneupolidy, trisomy, Down′s syndrome, ultrasound, maternal serum markers, fetal blood cells, fetal DNA. amniocentesis. chorionic villus sampling
|How to cite this article:|
Agarwal R. Prenatal diagnosis of chromosomal anomalies : Pictorial essay. Indian J Radiol Imaging 2003;13:173-88
Prenatal diagnosis of chromosomal anomalies employs a variety of techniques either as a screening procedure for relatively prevalent disorders or as a diagnostic procedure for known familial conditions. The former identifies an increased likelihood of a fetal abnormality in an apparently normal pregnancy, whereas the latter confirms or refutes the existence of an actual anomaly in a fetus believed to be at increased risk . Currently available prenatal non-invasive screening tests are ultrasonography and various biochemical tests, while CVS, amniocentesis, and fetal blood sampling are invasive diagnostic procedures. At present, these invasive procedures are considered as gold standard for the diagnosis of chromosomal anomalies or other genetic diseases. However, these procedures are associated with a finite risk of morbidity and mortality to the fetus. The risk associated with these tests and the cost of analysis preclude the adoption of methods for mass screening of pregnant women. Therefore, diagnostic procedures are only offered on a limited basis to high-risk pregnancies where the benefit outweighs the risk. In low-risk pregnancies, where there is low likelihood of diagnosing a chromosomal abnormality, prenatal diagnosis generally consists of screening procedures by means of ultrasound and maternal serum biochemistry.
An individual's estimated risk for a chromosomal abnormality is derived by multiplying the background risk ( based on maternal age, gestational age, history of previously affected pregnancies and, where appropriate, the results of previous screening by nuchal translucency and /or biochemistry in the current pregnancy) by the likelihood ratio of the specific defect ,,. On the basis of individual's estimated risk, "high-risk" pregnancies are those with;
1. Advanced maternal age (age 35 years or more at estimated date of delivery). Some authors also consider paternal age of approximately 50 years or older. 2. Family history (self, spouse, child, parent or sibling) of previous birth of a child with chromosome abnormality / multiple structural defects / ONTDs, or metabolic disorder. 3. Suspicious biochemical results. 4. Abnormal morphological scan. 5. Parent with a chromosome disorder. 6. Parent who are carriers of specific genetic defects such as cystic fibrosis, Tay-Sach dystrophy, sickle cell anemia, Falconis anemia, and thalassaemia.
The current protocol for prenatal diagnosis of chromosomal anomalies has limited effectiveness because, at present, there is no screening test available which is capable of specifically detecting parental predisposition for offspring with chromosomal abnormalities. On the other hand, the diagnostic procedures are not completely innocuous. Consequently, advances need to be made to develop non-invasive diagnostic tests, so that more pregnancies could benefit from such procedures. There has been recent research interest in the sampling of fetal material by non-invasive means. Such techniques include isolation of fetal blood cells and fetal DNA from maternal blood . But, currently, these methods do not have the performance, simplicity, or economy needed to replace existing techniques.
The most common reason for prenatal diagnosis of chromosome abnormalities is to look for evidence of trisomies, Turner syndrome and triploidy. Trisomy 13, 18, and 21 are the most common, with trisomy 21 comprising about half of all the trisomies identified. Various screening and diagnostic procedures used to detect common chromosomal abnormalities are discussed here.
| Screening procedures|| |
Ultrasound scanning is offered to all pregnant women. It is non-invasive and has no inherent procedure related loss. First-trimester sonography is offered mainly to confirm the gestational age, to identify singleton or multiple pregnancy and to measure nuchal thickness (NT). Second-trimester ultrasound is generally recommended at 19 to 21 weeks to detect fetal structural defects. There are two types of ultrasound markers for chromosomal abnormalities. The first category comprises major structural defects that are associated with various chromosome abnormalities, namely ventriculomegaly, duodenal atresia [Figure - 1], holoprosencephaly [Figure - 2], multicystic renal dysplasia [Figure - 3], severe hydrops [Figure - 4], diaphragmatic hernia [Figure - 5]a, omphalocele [Figure - 5] a,b, esophageal atresia, facial cleft, and congential heart defects (atrioventricular canal defect, VSD, ASD, PDA, hypoplastic left ventricle, aortic coarctation, transposition of great vessels, tetrology of Fallot, dextrocardia). It is advisable to offer fetal karyotyping to determine the possible cause and the risk of recurrence, even if these defects are apparently isolated. However, fetal karyotyping is not required in each and every major structural defect because certain defects such as small bowel obstruction and gastroschisis [Figure - 6] are a result of mechanical event rather than a teratogenic injury. Similarly, fetal karyotyping can be avoided in some major anomalies like skeletal dysplasias [Figure - 7] a,b where diagnosis by sonography is obvious. On the other hand some defects such as anorectal malformations [Figure - 8]a,b,c do not present till third-trimester and precise prenatal diagnosis by ultrasound is not possible. Offering of fetal karyotying in cases of isolated neural tube defects [Figure - 9] a,b is controversial. The other category comprises various minor biometric parameters and morphogenic soft markers such as nuchal translucency (NT) and cystic hygroma, pyelectasis, choroid plexus cyst (s), echogenic bowel, echogenic cardiac focus, shortened long bones, abnormalities of fetal hand and foot, and single umbilical artery. Although these soft markers have an association with abnormal karyotype, they may be found in a karyotypically normal fetus.
| Nuchal translucency (NT)|| |
NT [Figure - 10] refers to the subcutaneous space between the skin and the cervical spine in the fetus. The ultrasonographic findings of NT in the first-trimester of the pregnancy reportedly has been associated with fetal chromosome abnormalities including trisomies ,, and triploidy and Turner syndrome (45XO) ,,. Among karyotypically normal fetuses increased NT may be related to certain birth defects including cardiac septal defects, diaphragmatic hernia, renal defects, omphalocele, body-stalk anomaly, fetal akinesia syndrome, and certain skeletal dysplasias . Certain genetic defects and infections may also lead to increased NT . Various genetic defects associated with increased NT are Arthrogryposis, Noonan's syndrome, Smith-Lemli-Opitz syndrome, Stickler syndrome, Jarco-Levine syndrome, Miller-Dieker syndrome. Increased NT may be found in a normal fetus. Therefore, increased NT does not mean that the fetus is chromosomally abnormal but it does mean an increased risk for some disorders and birth defects.
NT measurements can be taken from the sagittal section of the fetus usually used to obtain the crown-rump length, or from a transverse suboccipitobregmatic view of the fetal head . NT values are crown-rump-length-dependent ,,,. Measurements equal to or more than 3mm in the first-trimester and more than 6mm in the second-trimester are considered as abnormal.
NT is apparently a powerful tool for the detection of aneupolidy, particularly Down's syndrome. For isolated nuchal edema, the risk for trisomy 21 may be 15 times the background ,. The estimated detection rate for Down's syndrome using NT at 10 to 14 weeks of gestation combined with maternal age is about 80% at a cut off risk of 1 in 300 or higher . However, there is considerable disagreement in the literature as to the precise Down's syndrome detection rate that can be expected with this form of sonography. An analysis recently by Wald  of currently available data on a variety of screening tests would suggest that NT is the least efficient of the screening strategies currently available. Therefore, it would be quite unwise to implement NT based screening sonography in isolation.
Cystic hygroma [Figure - 11] is caused by the malformation of the fetal lymphatic system and is found commonly in fetuses with Monosomy X (Turner syndrome), and other chromosomal anomalies. An important part of evaluation of nuchal membrane is the evaluation of the subtle signs of hydrops fetalis. Even in the presence of a normal karyotype, perinatal outcome is very poor in the presence of fetal hydrops.
| Choroid plexus cyst (s)|| |
Vast majority of cyst (s) [Figure - 12] is benign and usually disappears by 24-25 weeks. However, these cysts may be associated with chromosomal anomalies, primarily trisomy 18 but occasionally trisomy 21. Choroid plexus cysts have been reported to be associated with trisomy 18 in 1% to 6 % cases. For isolated choroid plexus cysts, the risk for trisomy 18 and trisomy 21 is about 1.5 times the background .
| Intracardiac echogenic foci|| |
Increased echogenicity (golf ball) [Figure - 13] located in chordae tendinae is seen in 3 to 5 % of fetuses and is considered by most investigators of no pathological significance. However, they are sometimes associated with chromosomal abnormalities particularly, trisomy 21. For isolated hyperechogenic foci the risk for trisomy 21 may be four times the background ,,.
| Hyperechogenic fetal bowel|| |
Hyperechogenic bowel [Figure - 14] has been described as a normal variant, but may also be associated with cystic fibrosis, meconium peritonitis, cytomegalovirus infection or trisomy 21. For isolated hyperechogenic bowel, the risk for trisomy 21 may be three times the background ,,.
| Mild hydronephrosis|| |
Minimal pyelectasis [Figure - 15] in the fetus is common and unlikely to be significant in every case . However, UPJ obstruction and reflux may manifest initially as mild fetal pyelectasis ,. In addition, karyotype abnormalities, remarkably trisomy 21, are reported to be associated with mild pyelectasis . For isolated mild hydronephrosis, the risk for trisomy 21 is about 1.5 times the background ,.
| Long bone biometry|| |
Short humeri and short femurs [Figure - 16] may be found in fetuses with Down's syndrome. Measurements are usually compared with BPD rather than menstrual age due to the uncertainty of the menstrual history. If the femur length is below 5th centile and all other measurements are normal, the fetus is likely to be normal but rather short. However, this finding is rarely related to dwarfism and occasionally trisomy 21 ,,,,.
| Fetal hand|| |
Abnormalities of fetal hand such as polydactyly, over-riding fingers, or abnormal hand positioning, especially if associated with polyhydramnios, have been reported to be associated with fetal chromosomal abnormalities.
| Club foot / Rocker bottom feet (positional deformities)|| |
Club foot has been associated with a variety of chromosomal abnormalities, especially trisomy 13 and 18 [Figure - 17] a,b. Whether or not infants with isolated club foot are at significantly increased risk of chromosomal abnormalities is still unresolved. Rocker bottom feet are also a feature of trisomy 13 and 18. The finding of this deformity should be a stimulus to detailed fetal examination and fetal karyotyping.
| Single umbilical artery|| |
A single umbilical artery [Figure - 17]b is found in 0.5% to 2% of newborns and is associated with structural or other anomalies in 20% to 50% of cases; usually relatively minor anomalies of the renal or genital tracts. Whether or not the presence of an isolated single umbilical artery is an indication for genetic studies is still uncertain.
| Intrauterine growth restriction|| |
A significant percentage of fetuses with chromosomal abnormalities are growth restricted. Some investigators have suggested the presence of IUGR alone is an indication for genetic studies.
Many additional abnormalities such as cerebellar hypoplasia, isolated pericardial effusion, sandal-foot, reduction defect of forearm, low set ears or shortened ear length, fetal cholecystomegaly, and polyhydramnios have been found to be associated with chromosomal anomalies. When these findings are seen in isolation, it is still controversial whether or not amniocentesis should be offered.
The sensitivity of ultrasonography for detection of fetal trisomic conditions varies with the type of chromosome abnormality, gestational age at the time of sonography, reasons for referral, criteria for positive sonographic findings, and the quality of the sonography . As an estimate, 1 or more sonographic findings can be identified in approximately 90% of fetuses with trisomy 13, 80% of fetuses with trisomy 18, and 50 % to 70% of fetuses with trisomy 21. Clusters of minor sonographic markers greatly increase the likelihood of karyotypic abnormality compared with a single minor marker . Inclusion of minor ultrasonographic markers in the genetic sonogram, in a high-risk population, allows the detection of 68% of fetuses with karyotypic abnormalities with a false-positive rate of 17% .
Since malformations of the heart are the most common birth defect in fetuses with serious chromosomal abnormalities, color Doppler ultrasound evaluation of the cardiovascular system can be used to improve the detection rate of these abnormalities. By the inclusion of color Doppler sonography in genetic ultrasound, 96% of fetuses with Down's syndrome, 98% of all trisomies, and 88 % of all chromosomal abnormalities can be detected . A complete normal ultrasound examination result reduces the risk of abnormal karyotype by 62%.
2. Biochemical tests
A large number of serum analytes have been found to be associated with chromosomal abnormalities. Various principal biochemical analytes currently available for the prenatal screening of chromosomal abnormalities during first and second-trimester of pregnancy are; pregnancy associated plasma protein-A (PAPP-A), maternal serum alpha-feto-protein (MSAFP), free-beta hCG, total hCG, unconjugated estriol (uE3), and inhibin-A. PAPP-A and free-beta hCG are only biochemical markers identified to be of value in first-trimester screening. Free-beta hCG is the only marker that is effective in both the first and second-trimester pregnancy. Other serum markers such as urea-resistant neutrophil alkaline phosphatase and Ca-125 are under study. The value of various urinary markers such as beta-core hCG, total estriol and free beta-hCG are currently under study and the use of urine in future screening programmes may be a practical possibility.
The results of biochemical tests are expressed as multiple of median (MoM, compares a woman's value to median values taken from the general population in a certain community of normal pregnant women). However, the degree of risk to individual pregnant woman relies on combining the results with maternal age in a complex mathematical algorithm using commercially available software programs. The test is interpreted as positive or negative according to whether or not the risk exceeds a fixed cut-off point.
| PAPP-A|| |
It is a homotetrameric glycoprotein (metzincins family of metalloproteases) which is synthesized in chorionic villi . It can be measured in maternal serum; its concentration increases rapidly after 7th week of pregnancy and its potential clinical usefulness is greatest in the first trimester (10th to 14th week of gestation). When the fetus is affected with trisomy 21, PAPP-A levels are decreased by more than half . Low PAPP-A is also associated with trisomy 18 and 13. Using PAPP-A alone, detection rate of Down's syndrome is about 40%. When PAPP-A was combined with maternal age, the detection rate increased to 50% with a 5% screen-positive rate . Decreased production of PAPP-A may cause intrauterine growth restriction  as this hormone control the level of insulin -like growth factors (IGF) in the placenta.
| Msafp|| |
MSAFP is a glycoprotein produced by the fetal yolk sac and fetal liver. Fetal plasma concentration increases to a maximum (approximately 3.0-4.0 g/L) between 13-14 weeks of gestation. Maternal serum levels peak at about 30 weeks (about 250 mg/L). After birth, maternal and infant AFP rapidly declines. High MSAFP levels may occur in the following conditions;
1. Underestimated gestational age 2. Multiple gestation. 3. Neural tube defects (anencephaly, spina bifida, encephalocele). 3 Abdominal wall defects (omphalocele, gastroschisis) 4. Various other fetal abnormalities such as hydrocephaly, microcephaly, cystic hygroma, cyclopia, tetralogy of Fallot, duodenal atresia, congenital nephropathies, sacrococcygeal teratoma, hydrops fetalis and Turner's syndrome without hygroma. 5. Complications of pregnancy ( fetal distress, growth retardation, early
intrauterine death, placental defects, abdominal pregnancy, and maternal proteinuric preeclampsia). 6. Congenital fetal neoplasms, and maternal AFP producing neoplasms.
Low MSAFP levels may be associated with 1. Incorrect pregnancy dating (less advanced than originally thought). 2. Complications of pregnancy (missed abortion, spontaneous abortion, late fetal death, molar pregnancy, choriocarcinoma). 3. Some normal pregnancies. 4. Large-for-dates. Very low MSAFP predicts an unusually high rate of large birth weight infants, with increased fetal, intrapartum, and neonatal consequenses . 5. MSAFP less than the median may indicate an increased risk of chromosomal abnormalities such as trisomy 21 and trisomy 18. The level of MSAFP in Down's syndrome pregnancies are about 72% of the normal values for weeks 14 to 21. Using maternal age and MSAFP level, the detection rate of Down's syndrome pregnancies is about 25-33%, at a false positive rate of 5% ,.
| Total hCG|| |
hCG is a dimeric glycoprotein composed of two non-covalently linked polypeptide sub-units, alpha and beta. It is first secreted by the fertilized ovum and later by placental tissue. Serum hCG levels increase exponentially between 3-10 weeks of pregnancy. Levels reach a peak during the first-trimester (about 100000 m IU/ml) and decline during the second and third-trimesters. In normal second-trimester maternal sera, the level of intact hCG ranges from 20,000-50,000 mIU/ml. In trisomy 21 pregnancies, second -trimester hCG levels are elevated varying from 2.04 to 2.5 MoM or greater while in trisomy 18 and 13, hCG levels are lower than normal. Using maternal age and hCG levels, Down's syndrome detection rate is about 60 % at a false positive rate of 6.7 % . Very high levels of hCG suggest trophoblastic disease.
Various workers found a significant increase in the levels of free beta-hCG in trisomy 21, and concluded that this biochemical analyte is superior to intact hCG for the detection of trisomy 21 ,,. Second-trimester free beta-hCG median in Down's syndrome affected pregnancies is about 2.69, compared to 1.0 in unaffected pregnancies. The levels of this analyte are reduced in the blood of women carrying fetuses with trisomy 18 (second trimester median = 0.20, compared to 1.0 in unaffected fetuses). Using maternal age and free beta-hCG, a detection rate of 61.0% at a false positive rate of 8.3% was found .
| Unconjugated estriol (uE3)|| |
The substrate for estriol begins as dehydroepiandrosterone (DHEA) made by the fetal adrenal glands. This is later hydroxylated in fetal liver and cleaved by steroid sulphatase in placenta where unconjugated fraction converts to uE3. The amount of estriol in maternal serum is dependent upon a viable fetus, a properly functioning placenta, and maternal wellbeing. In normal pregnancies, uE3 levels increase from about 4 nmol/L at 15 weeks gestation to about
40 nmol/L at delivery. uE3 tends to be lower when trisomy 21or 18 is present and when there is adrenal hypoplasia with anencephaly.
Second-trimester maternal serum uE3 levels in Down's syndrome pregnancies are approximated 75% of the values expected in normal pregnancies ,,. Using maternal age and uE3 levels detection rate of about 45.7% at a false positive rate of 9.1 % was found .
| Inhibin-A|| |
Inhibin-A is a heterodimeric glycoprotein of placental origin similar to hCG. Inhibin-A levels in maternal serum are relatively constant through the 15th-18th week of pregnancy. Maternal serum levels of inhibin-A are twice as high in pregnancies affected by Down's syndrome as in unaffected pregnancies while in trisomy 18, inhibin-A levels are lower than normal. Inhibin-A is used with three other analytes (MSAFP, hCG, uE3) and maternal age to characterize more accurately Down's syndrome risk, and a reduction of the false positive rate was detected ,.
Currently available evidences suggest that sensitivity of individual maternal serum markers is substantially low. To improve the sensitivity and specificity of biochemical markers, various combinations of 2, 3, or 4 analytes are offered during first and / or second-trimester screening. But before considering various combinations, it is necessary to take into account the degree of correlation between the markers. There is great controversy in literature about which analytes are most effective and which combination provides the best results.
| Various combinations of analytes include;|| |
1. First-trimester maternal serum double test using PAPP-A and free-beta hCG. This is vastly more effective than any other screening program and is of great advantage because it is available in the first-trimester. The disadvantage is that the test will not detect neural tube defects, so a MSAFP test will still need to be done. After combining PAPP-A and free beta-hCG with maternal age, detection rate of aneuploidy is about 60% at a 5% screen-positive rate ,,,,,.
2. Second-trimester screening includes; double test (MSAFP+ free-beta hCG or total hCG), triple test (MSAFP+hCG+uE3), and quad screen test (MSAFP+hCG+uE3+inhibin-A). When an ultrasound scan is used to estimate gestational age the Down's syndrome detection rate for a 5% false positive rate is estimated to be 59% using the double test (AFP and hCG), 69% using the triple test (AFP,hCG,uE3), and 76% using the quad test (AFP,hCG,uE3, inhibin-A), all in combination with maternal age . Main disadvantage of second-trimester screening is the timing of the test. By the time a definitive diagnosis is made via amniocentesis (after a positive screen result), the option of termination of pregnancy can be difficult.
MSAFP is always included as a component of second-trimester biochemical screening because this analyte is widely used for the detection of ONTDs at this stage of pregnancy . Addition of uE3 as an analyte for prenatal screening is controversial. Some authors pointed out that inclusion of this analyte does not improve detection rates ,, where as in another study  a fall in detection rate was noticed. On the other hand, some workers rely on the usefulness of uE3 as a serum marker ,. In a study , it was found that double test is not worse than the triple test and the double test is preferred because of lower running cost. Comparing free beta-hCG and total hCG, it was found that free beta hCG is better option because it improves the Down's syndrome detection efficiency by 10 % over total hCG  at a lower false positive rate ,,,,,.
Review of the literature suggests that the combined use of free beta-hCG and AFP  instead of total hCG, AFP and uE3, is better screening test because it is more effective, less expensive, and is not limited to 16-20 weeks gestation ,. The addition of uE3 and inhibin-A adds no significant advantage to the double test. However, some workers recommend triple test , while some rely on quad test for better results ,. Various trials such as"SURUSS" trial in the United Kingdom and the "FASTER" trial in the United States are evaluating various screening tests in a population to document Down's syndrome detection rate for all forms of first and second-trimester screening.
| Combined screening|| |
Since maternal biochemical and sonographic markers are largely independent, combined risk estimate results in even higher detection rate than either alone ,,,,. Thus combination of a multiple marker test (PAPP-A and free b-hCG) and an ultrasound at 11 to 14 weeks which is targeted to look NT, and maternal age , gives a detectable rate of aneuploidy of about 90 % with an invasive testing rate of about 5% ,,,. But in many high-risk situations this may still leave the patient at risk.
| Integrated screening|| |
Wald, et al  described a screening method based on the integration of sequential measurements of the first and second-trimester markers into a single test. The integrated test includes measurements of PAPP-A and NT in the first-trimester and measurements of MSAFP, uE3, hCG, and inhibin-A in the second-trimester. The integrated test can achieve a high detection rate with a much lower false positive rate (0.9%) than screening based on markers measured in either trimester alone . Consequently the need for amniocentesis or CVS is reduced by four fifths, with a similar reduction in the loss of unaffected fetuses . The estimates of the integrated test's performance are based on there being little or no correlation between the first and second-trimester markers used with the exception of free beta-hCG and total hCG ,. Disadvantage of the test is that it is expensive, and option of making the diagnosis in the first-trimester is eliminated.
Recently, Azuma M, et al  used Lens culinaris agglutinin reactive alpha-fetoprotein ratio for the detection of fetal Down's syndrome in combination with traditional serum markers such as AFP, hCG and uE3 and found a detection rate of 83.9% with a 5.1% false positive rate.
Various factors affect the accuracy of biochemical tests. Therefore, adjustments are made to take account of these factors when categorizing the result as screen positive or screen negative. These factors are:
- Gestational age: Measured concentrations of the serum markers vary with gestational age ,,,,,, Between 9 to 14 weeks, maternal serum free beta-hCG decreases, median free beta-hCG also decreases while median PAPP-A increases. Between 14-22 weeks, Median MSAFP and median uE3 increases, median hCG decreases while median inhibin-A is less affected.
- Maternal weight: Maternal weight has a significant effect on the screening process ,. There is inverse correlation between body weight and concentration of biochemical markers. If the volume of distribution is greater, the concentration of AFP will be smaller . Maternal weight also has a significant inverse correlation on inhibin-A levels . PAPP-A and free beta-hCG also show a small but significant negative correlation ,. But there is no correlation for uE3 .
- Smoking: Maternal smoking has a small effect on overall screening performances ,. Women who smoke are more likely to produce a small amount of PAPP-A.
- Effect of parity: Parity significantly affects the mean MoM of hCG but did not affect the values for uE3 or MSAFP ,,.
- Multiple pregnancies: On an average, the levels of MSAFP and free beta-hCG were twice as high in twins and over three times as high in triplets .
- Difference between races of ethnic groups: Medians are significantly different in races of ethnic groups . Black women, on an average, have higher levels of MSAFP than Caucasian, Asian or Hispanic women.
- Insulin-dependent diabetes mellitus: MSAFP levels in IDDM have shown an approximately 20% decrement while uE3 and inhibin-A levels are reduced to a smaller extent (about 6% and 12% lower respectively). Thus, levels of biochemical analytes have to be adjusted, since that has an effect on increasing the detection rate . However, according to Evans MI, et al , with current methodologies, the 20% correction factor for IDDM erroneouly overcorrected, and weight correction for diabetic status should be abondoned.
| Conclusions of multiple marker screening test:|| |
- Maternal blood screening is originally developed for pregnant women who are at a 'low-risk' for disorders being screened. However, in certain situations maternal serum marker screening can be assayed in women > or =35 years. .
- Gestational age must be accurately known. First-trimester screening is offered between 10 to 14 weeks of gestation, while second-trimester screening tests are given between 14 and 22 weeks of pregnancy, with 16 to 18 weeks (when the hormone levels are most consistent) being the optimum time. Recently Muller F, et al  assessed the diagnostic value of maternal serum marker screening at 18-35 weeks and concluded that biochemical screening is feasible at 18 weeks and later, which may be of interest in selected cases.
- Multiple gestation screening is not as sensitive as singleton screening with biochemical analysis.
- Screening utilizing biochemical test, NT and maternal age mainly identifies aneuploidy and some other chromosomal abnormalities only and therefore shall miss majority of other non-Down, non-trisomy 18 chromosome abnormalities, nor does it identify other physical or mental birth defects.
- A low PAPP-A, low MSAFP, low uE3, and high free beta-hCG, and high inhibin-A levels are associated with higher risk for Down's syndrome while low levels of all hormones suggest an increased risk for trisomy 18. In trisomy 13, PAPP-A and free beta-hCG levels are low but detection rate using second-trimester analytes is poor.
- Although screening protocol has a 90 % pickup rate of aneuploidy, it is not diagnostic. Hence, suspicious screening results will tell of an increased risk of a problem, but not diagnose the problem as being present or being absent. Therefore, a negative screening result may falsely reassure many women who are carrying an affected fetus. Conversely, a false positive result may culminate in termination of a normal pregnancy. The main aim of screening test is to identify a group of women at significantly high-risk of having an affected child to justify the offer of a diagnostic test.
3. Non-invasive screening using fetal blood cells and fetal DNA.
(a) Fetal blood cells:
The fetal and maternal circulations are separated by the placental membranes, but this barrier is incomplete to cellular trafficking. Bi-directionality and bimodality (cell and cell-free DNA) of fetomaternal trafficking is an established fact. Fetal nucleated cells such as trophoblasts, erythrocytes and white blood cells are found in maternal blood, and have been widely pursued as potential substrates for noninvasive prenatal diagnosis. However, concentration of these cells in maternal blood is very low (1fetal cell in 103-108 maternal cells) ,, and therefore isolation of these cells for cytogenetic analysis requires expensive euipments and great expertise. Isolation of erythroblasts has attracted most attention because they are abundant in early fetal blood, they are extremely rare in normal adult blood and their half-life in adult blood is only about 30 days. Relatively specific monoclonal anibodies against these cells are also available. Trophoblastic cells and white cells are not used for prenatal screening because trophoblastic cells are cleared by maternal lungs whereas half life of the white cells is very long which may lead to contamination from previous pregnancies.
A combination of sophisticated physical and immunological methods are used for the identification, isolation and enrichment of different types of fetal blood cells from maternal blood obtained at 12-16 weeks of gestation. Physical methods include triple density gradient centrifugation and micromanipulation techniques while immunological methods include the use of magnetically labelled or fluorescent monoclonal antibodies such as anti-CD71 (transfferin receptor). Commonly used immunological methods are, magnetic cell sorting (MACS) or fluorescence activated cell sorting (FACS) ,,. By these methods the fetal cells can be enriched to about 1 in 10-100 materanl cells. Enriched cells are used for the detection of specific chromosomes by fluorescent in situ hybridization (FISH) and for the analysis of fetal genetic loci by single cell PCR. FISH involves the hybridization of DNA probes representing a specific chromosome or chromosomal region to target DNA such as metaphase chromosomes or interphase nuclei.
Fetal trisomy is suspected if some of the enriched cells show three-signal nuclei rather than the normal two. Over the past decade, progress has been made towards the isolation and analysis of fetal blood cells from maternal blood, using various enrichment strategies and analysis by fluorescent in situ hybridization with choromosome-specific probes and PCR. It is now possible to identify simultaneously all major chromosomal abnormalities by the use of multicolor probes directed against chromosomes 21, 18, 13,Y and X in interphase nuclei. Another method that is currently being explored involves culturing fetal blood cells . The sensitivity for detecting aneuploidy using fetal cells is competitive with first or second-trimester maternal serum screening with the advantage that the invasive testing rate may be as low as 0% rather than 5%. But the current technology precludes application of this concept for mass population. However, fetal cells might be analyzed only after a positive serum or ultrasound finding. If fetal aneuploid cells are not recovered, an invasive diagnostic procedure could be avoided.
(b) Fetal DNA
Isolation of fetal cells from the cellular fraction of maternal blood needs expensive and advance equipment because of the rarity of such cells. Recently, there has been much interest in the use of the non-cellular portion of blood, namely plasma, for molecular analysis diagnosis ,,. Fetal DNA has been identified in the plasma of pregnant women at concentrations much higher than those present in the cellular fraction. Until recently, it was assumed that fetal DNA detected in maternal plasma was cell free and a definitive diagnosis of fetal chromosomal aneuploidies was not thought possible. Studies now indicate that some fetal DNA originates from intact fetal cells. Trophoblasts may be the predominant cell population involved in the liberation of fetal DNA into the cell-free fraction . It was found that the absolute concentration of fetal DNA in maternal serum increases with gestational age, with a sharp rise near the end of the pregnancy. Fetal DNA is cleared rapidly from maternal blood after delivery with a half-life of minutes. Increase in fetal DNA in maternal plasma has been noticed in pregnancies affected by fetal trisomy, and in premature labour, and preeclampsia . Using fetal DNA in maternal plasma for the screening of fetal chromosome aneuploidies is possible, especially in conjugation with other established serum markers . The median fetal DNA concentration in Down's syndrome cases was found to be 1.7 times higher than in controls . Second-trimester cell-free fetal DNA estimation gave a 21% detection rate at a 5% false-positive rate . When added to quadruple marker screening, fetal DNA estimation modestly increased the screening performance above what is currently available in the second-trimester . The relative ease and reliability with which fetal DNA can be detected have thus opened new possibilities for non-invasive prenatal diagnosis ,.
| Invasive diagnostic procedures|| |
Diagnostic tests such as amniocentesis and CVS are developed for pregnancies at "high-risk". These tests are offered for definitive diagnosis of fetal chromosome and / or genetic abnormality. Although amniocentesis and CVS test for chromosome abnormalities (almost 99% detection rate), a normal test does not mean that the fetus is free of all structural defects; it just means that the fetus is free of the specific abnormalities evaluated.
1. Chorionic villus sampling
CVS is a prenatal test that involves taking a sample of some of the placental tissue. Main complications of CVS include severe transverse limb defects and oromandibular-limb hypogenesis . Possible mechanism of severe transverse limb abnormalities is hypoperfusion, embolization and release of vasoactive substances due to trauma during the procedure. There is strong association between the severity of the defect and the gestation at sampling ,. Decreasing risk and a trend from proximal to distal limb damage with increasing gestational age at CVS provide biologic plausibility for a true association with limb reduction defects ,. CVS as early as 8 weeks of gestation may lead to amputation of whole limb while sampling at 10 weeks only affects terminal phalanxes ,. Thus, to avoid severe limb defects, CVS prior to 11 weeks of gestation should be discouraged. The increase in the miscarriage rate following this procedure is about 0.5% above the background risk for miscarriage, which is 2-3% at 10-12 weeks of pregnancy. Various trials compared CVS in first-trimester and amniocentesis in the second-trimester and concluded that both procedures are equally effective and safe with similar rates of procedure-induced fetal loss at experienced centers ,,,.
The main advantage of CVS over amniocentesis is that prenatal diagnosis is achieved during the first-trimester, which allows a couple the opportunities to consider their options earlier in the pregnancy in the event of an abnormal result. However, screening for ONTDs cannot be achieved through CVS. The main indication for repeat CVS is mosaicism.
Amniocentesis was first used for prenatal diagnosis in the 1950's and the feasibility of culturing and karyotyping amniotic fluid cells was first demonstrated in the late 1960s ,. Although the exact risk associated with amniocentesis is controversial, it is also not a completely innocuous procedure and can result in various complications such as spontaneous abortion, premature labour, placental abruption, intrauterine death and neonatal death. Other reported procedure-related complications include increased risk of respiratory distress syndrome and pneumonia in neonates ,,, talipes and dislocation of the hip, postprocedural amniotic fluid leakage of amniotic fluid, vaginal bleeding, chorioamnionitis, amniotic band formation and rare needle puncture of the fetus. Amniocentesis may results in future reproductive complications secondary to sensitization , to Rh and other rare antigens such as Kell.
Amniocentesis can be performed as early as 11-13 weeks of gestation. But at this stage of pregnancy, the procedure is not only technically difficult to perform, it is also associated with increased incidence of total fetal loss, talipes equinovarus and post-procedural amniotic fluid leakage . Incidence of failed culture is also high in early amniocentesis. Thus, the procedure should not be performed before 13 weeks gestation unless there are special circumstances.
Potential advantage associated with amniocentesis includes; 1.The amniotic fluid can be tested to measure the amount of AFP, which is a diagnostic test for detecting ONTDs 2. Possibility of an abnormal chromosome result due to chromosomal mosaicism confined to the placenta is reduced.
| To conclude|| |
- A careful past history of any congenital malformation, deformation, disruption structural defect, syndrome, association, a sequence, or metabolic disorder in the family including self, spouse, child, parent or siblings should be taken. Such history will identify a structural defect related to a mechanical event or a major teratogenic injury and will differentiate a high-risk and a low-risk pregnant woman. Information about maternal age, LMP, parity, DM, smoking habit, and taking of any medicine, particularly anti seizure drugs, should be obtained. Such enquiry helps in risk assessment during biochemical analysis.
- All pregnant women should be offered first-trimester ultrasound, and second-trimester sonography and echocardiography. When a major life-threatening abnormality is found, termination of the pregnancy is offered. But before that, amniocentesis must be carried out for karyotyping which helps in future counseling. If a major defect is not life threatening and is surgically correctable by intrauterine or postnatal surgery, karyotyping is offered to exclude an underlying chromosomal abnormality. When a minor soft marker (s) is detected, a thorough check is made for the other features of the chromosomal defect known to be associated with that marker and accordingly non-invasive or invasive test is advised.
- All low-risk pregnant women should under go first-trimester and / or second-trimester biochemical test. Sonographic finding and relevant clinical history must be provided to the laboratory performing the biochemical test so as to calculate the risk of a chromosomal abnormality. If the risk exceeds a fixed cut off point then the pregnancy is treated as a high-risk pregnancy.
- According to American College of Obstetrician and Gynecologists and the American College of Medical Genetics, high-risk pregnant women should be referred for genetic counseling, ultrasound, and invasive diagnostic test.
- With future technical refinements, prenatal diagnosis by maternal plasma DNA analysis could reduce our reliance on invasive investigative methods, leading to safer diagnostic protocol for mother and fetus.
| References|| |
|1.||Royal college of Obstetricians and Gynaecologists, Royal College of Paediatrics and Child Health. Background evidence supporting the guidelines. In: Fetal abnormalities. Guidelines for screening, Diagnosis and Management. London, UK:RCPCH, RCOG,1997:5. |
|2.||Snijders RJM, Nicolaides KH. Assessment of risks. In Ultrasound markers for fetal chromosomal defects. Carnforth, UK: Parthenon publishing, 1996: 109-13. |
|3.||Snijders RJM, Sebire NJ, Faria M, et al. Fetal mild hydronephrosis and chromosomal defects: relation to maternal age and gestation. Fetal Diagn Ther 1995;10:349-55. |
|4.||Snijders RJM, Shawa L, Nicolaides KH. Fetal choroid plexus cysts and trisomy 18; assessment of risk based on ultrasound findings and maternal age. Prenat Diagn 1994;14:1119-27. |
|5.||Chiu Rossa WK, LO YMD. Fetal DNA in Maternal Plasma : Biological and Diagnostic implications. HKJGOM 2000; 1(2):116-120. |
|6.||Bronshtein M, Rottem S, Yoffe N, Blumenfeld Z. First-trimester and early second-trimester diagnosis of nuchal cystic hygroma by transvaginal sonography: diverse prognosis of the septated from the nonseptated lesion. Am J Obstet Gynecol 1989; 161:78-82. [PUBMED] |
|7.||Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-869. |
|8.||Nicolaides KH, Brizot ML, Snijders RJ. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy. Br J Obstet Gynaecol 1994; 101:782-786. |
|9.||Souka AP, Snijders RJM, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1;1998; 391-400. |
|10.||Nicolaids KH, Azar G, Snijders RJM, Gosden CM. Fetal nuchal edema: associated malformations and chromosomal defects. Fetal Diagn Ther 1992;7:123-31. |
|11.||Comas C, Martenez JM, Ojuel J, et al. First-trimester nuchal edema as a marker of aneuploidy. Ultrasound Obstet Gynecol 1995;5:26-29. |
|12.||Schuchter K, Wald N, Hackshaw AK, et al. The distribution of nuchal translucency at 10-13 weeks of pregnancy. Prenat Diagn 1998;18:281-286. [PUBMED] [FULLTEXT]|
|13.||Nyberg DA, Luthy DA, Resta RG, Nyberg BC, William MA. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998; 12:8-14. |
|14.||Donnenfeld AE, Cartson DE, Palomaki GE, Librizzi RJ, Weiner S, Platt L. Prospective multicenter study of second trimester Nuchal skin fold thickness in unaffected and Down syndrome pregnancies. Obstet Gynecol 1994; 84:844-47. |
|15.||Snijders RJM, Nobel P, Sebire N, Souka A, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 352:1998: 343-346. |
|16.||Wald N, Chasen ST, Skupski DW, et al. First-Trimester Nuchal Translucency Screening. Ultrasound Med 2002; 21: 481-487. |
|17.||Simpson JM, Cook A, Sharland G. The significance of echogenic foci in the fetal heart: a prospective study of 228 cases. Ultrasound Obstet Gynecol 1996; 8: 225-28. |
|18.||Vibhakar NI, Budorick NE, Sciosia AL, et al. Prevalence of aneuploidy with a cardiac intraventricular echogenic focus in an at-risk patient population. J Ultrasound Med1999; 18:265- 68. |
|19.||Bromley B, Doubilet P, Frigoletto FD Jr, Krauss C, Estroff JA, Benacerraf BR. Is fetal hyperechoic bowel on second-trimester sonogram an indication for amniocentesis ? Obstet Gynecol 1994; 83:647-51. |
|20.||Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus-correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 1996; 175:724-29. |
|21.||Gunn TR, Mora JD, Peose P. Antenatal diagnosis of urinary tract abnormalities by ultrasonography after 28 weeks of gestation: incidence and outcome. Am J Obstet Gynecol 1995;172:479-486. |
|22.||Corteville JE, Grane JP. Congenital hydronephrosis correlation of fetal ultrasonographic findings with infant outcome. Am J Obstet Gynecol 1991;165:384-388. |
|23.||Agar PH, Coleman BG, Mintz MC, et al. Routine fetal genito urinary tract screening. Radiology 1985; 150:485-489. |
|24.||Vintzileos AM, Campbell WA, Guzman ER, et al. Second-trimester ultrasound markers for detection of trisomy 21: which markers are best ? Obstet gynecol 1997; 89:941-44. |
|25.||Wickstrom EA, Thangavelu M, Parilla BV, et al. A prospective study of the association between isolated fetal pyelectesis and chromosomal abnormality. Obstet Gynecol 1996; 88: 379-82. |
|26.||Cuckle H, Wald N, Quinn J, Royston P, Butler L. Ultrasound fetal femur length measurement in the screening for Down's syndrome. Br J Obstet Gynaecol 1989; 96:1373-78. |
|27.||Grandjean H. Sarramon MF. Femur/foot length ratio for detection of Down syndrome: results of a multicenter prospective study. The Association Francaise pour le Depistage et la Prevention des Handicaps de l'Enfant study group. Am J Obstet Gynecol 1995; 173 :16-19. |
|28.||Johnson MP, Michaelson JE, Barr M, et al. Combining humerus and femur length for improved ultrasonographic identification of pregnancies at increased risk for trisomy 21. Am J Obstet Gynecol 1995; 172: 1229-35. |
|29.||Owen J, Wenstrom KD, Hardin JM, et al. The utility of fetal biometry as an adjuent to the multiple-marker screening test for Down syndrome. Am J Obstet Gynecol 1994; 17:1041-46. |
|30.||Vintzileos AM, Egan JF, Smulin JC, et al. Adjusting the risk for trisomy 21 by a simple ultrasound method using fetal long-bone biometry. Obstet Gynecol 1996; 87::953-58. |
|31.||Nyberg DA, Souter VL. Sonographic markers of fetal trisomies: second trimester. J.Ultrasound Med 2001 Jun; 20 (6): 655-74. |
|32.||DeVore GR, Alfi O. The use of color Doppler ultrasound to identify fetuses at increased risk for trisomy 21: an alternative for high-risk patients who decline genetic amniocentesis. Obstetrics and Gynecology 1995 Mar: 85(3) : 378-86. |
|33.||Brayan D, Sohl MD, Angela L, et al. Utility of minor ultrasonographic markers in prediction of abnormal fetal karyotype at a prenatal diagnostic centre. Am J Obstet Gynecol 1999;181:890-903. |
|34.||Sohl BD, Scioseia AL, Budorick NE, Moore TR. Utility of minor ultrasonographic markers in the prediction of abnormal fetal karyotype at a prenatal diagnostic center. Am J Obstet Gynecol 1999 Oct; 181 (4) : 898-903. |
|35.||Casals E, Ajbar C, Martinez JM, et al. "First trimester biochemical markers for Down syndrome". Prenat Diagn.1999; 19:8-11. |
|36.||de Graaf IM, Pajkrt E, Bilardo CM, et al. Early pregnancy screening for fetal aneuploidy with serum marker and nuchal translucency. Prenat Diagn 1999;19:458-62. |
|37.||Spencer K. Souter V, Tul N, et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynaecol 1999;19:458-62. |
|38.||Cuckle HS, Sehmi IK, Jones R, Mason G. Low maternal serum PAPP-A and fetal viability. Prenat Diagn 1999; 19(8): 788-790. |
|39.||Baschat AA, Harman CR, Farid G et al. Very low second-trimester maternal alpha-fetoprotein: Association with high birth weight. Obstet Gynecol 2002 Apr;99(40:531-36. |
|40.||Cuckle HS, Wald NJ, Thompson SG. Estimating a women's risk of having a pregnancy associated with Down's syndrome using her age and serum AFP level. Br J Obstet Gynaecol 1987;94:387-402. |
|41.||Goodburn SF et al. Second trimester maternal serum screening using AFP, hCG and Ue3. Prenat Diagn 1994 May;14(5).391-402. |
|42.||Wald NJ, Kennard A, Hackshaw A, et al. Antenatal screening for Down's syndrome. J Med Screen 1997; 4: 181-87. |
|43.||Elder-Geva T, Hochberg A, deGroot et al. High maternal serum chorionic gonadotropin level in DS pregnancies is caused by elevation of both subunits messenger RNA level in trophoblasts. J Clin Endocrinol Metabol 1995;80:3528- 31. |
|44.||Wenstrom KD, Owen J, Chu DC, Boots L. Free beta-hCG subunits versus intact hCG in Down syndrome screening. Obstet Gynecol 1997 Sep;90(3):370-374. |
|45.||Spencer K, Paul Carpenter. Prospective study of prenatal screening for Down's syndrome with free beta-hCG. B M J 1993; 307:764-769. |
|46.||Spencer K, Marki JN. Early detection of Down syndrome using free beta-hcg. Ann Clin Biochem 1992, 29;349-350. |
|47.||Spencer K, Coombes J, Selby C, et al. Free beta-hCG in Down syndrome screening: A multicenter study of its role compared with other biochemical markers. Ann Clin Biochem 1992;29:506-518. |
|48.||Olivier Dedeystere. Interet du dosage de la sous-unite beta libre d' hCG dans le depistage prenatal de la trisomie 21. Immunoanal Bio Spec 1993(8) 177-179. |
|49.||Wald NJ, Densem JW, Knight PG. Prenatal screening for Down's syndrome using Inhibin-A as a serum marker. Prenat Diag 1996 Feb;16(2): 143-153. |
|50.||Watt HC, Wald NJ, Huttly WJ. The pattern of maternal serum inhibin-A concentrations in the second -trimester pregnancy. Prenat Diagn 1998 Aug;18 (8):846-48. |
|51.||Wald NJ, Gerge L, Smith D, et al. On behalf of International Prenatal Screening Research Group. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. Br J Obstet Gynaecol 1996; 104:407-12. |
|52.||Berry E, Aitken DA, Crossley JA, et al. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimester. Br. J Obstet Gynaecol 1997:104;811-17. |
|53.||Haddow JE, Palomaki GE, Knight GJ, et al. Screening for maternal serum for fetal Down's syndrome in the first trimester. N Engl J Med 1998: 338: 955-61. |
|54.||Wheeler DM, Sinosich MJ. Prenatal screening in the first trimester of pregnancy. Prenat Diagn 1998;18:537-43. |
|55.||Tsukerman GL, Gusina NB, Cuckle HS. Maternal serum screening for Down syndrome in the first trimester: experience from Belarus. Prenat Diagn 1999: 19; 499-504. |
|56.||Lemay C, Roussel-Mizon N, Thepot F, et al. Maternal serum screening for fetal Down syndrome, a retrospective study. Clin Chim Acta 238, 1995;151-162. |
|57.||Loncar J, Barnabei VM, Larsen JW. Advent of maternal serum markers for Down's syndrome screening. Obstet Gynecol Survey 1995 APR; 50(4):316-32. |
|58.||Reynolds T, John R, Spencer K. The use of unconjugated estriol in Down syndrome screening is unproven. Clin Chem 1993;39; 2023-25. |
|59.||David M, Merksamer R, Israel N, Dar H. Unconjugated estriol as maternal serum marker for the detection of Down syndrome pregnancies. Fetal Diagn Ther 1996 March;11(2):99-105. |
|60.||Kellner LH, Weiner Z, et al. Triple marker (AFP,uE3,hCG) versus AFP+free beta-subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study. Am J Obstet Gynecol 1995 Oct; 173(4):1306-1309. |
|61.||Knight GJ, Palomaki GE, et al. Hcg and the free beta subunit as screening tests for Down syndrome. Prenat Diagn 1998;18(3): 235-45. |
|62.||Extermann P, Bischof P, Marguerat P, et al. Second -trimester maternal serum screening for Down's syndrome: free beta-hCG and AFP, with or without uE3, compared with total hCG, alpha-fetoprotein and uE3. Human Reproduction vol 13 (1); 1998:220-223. |
|63.||Macri JN, Spencer K, Aitken D, et al. Screening for Down syndrome. Prenat Diagn 1993; 13:557- 62. |
|64.||Hsu JJ, Hsich TT, Hsich FJ. Down syndrome screening in an asian population using AFP and free beta-hCG:a report of the Taiwan Down syndrome screening group. Obstet Gynecol 1996 Jun;87(6):943-947. |
|65.||P.Rozenberg-A. Gillet Depistage biologique et echographique de la trisomie 21. Realitiesen Gynecologie-Obstetrique N8-Janvier 1996. Cigarette smoking and levels of MSAFP, uE3 and hCG impact on Down syndrome screening. Obstet Gynecol 1993 May; 81 (5Pt1): 675-678. |
|66.||Spencer K. Second trimester prenatal screening for Down's syndrome using alpha fetoprotein and free beta hcg: a seven year review. Br Obstet Gynaecol 1999 Dec;106(12):1287-93 |
|67.||Marcri JN, Spencer K. Toward the optimal screening protocol for Down syndrome screening. Am J Obstet Gynecol. 1996;174 (5);1668-1669. |
|68.||Ozturk M, Milunsky A, Brambati B, et al. Abnormal maternal levels of h CG subunits in trisomy 18. Am J Med Genet 1990; 36:480-83. |
|69.||Kellner LH, Weiss RR, Weiner Z, et al. The advantages of using triple marker screening for chromosomal abnormalities Am J Obstet Gynecol 1995 Mar; 172(3): 831-836. |
|70.||Wald NJ, Hackshaw AK. Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome. Prenat Diagn 1997;17:821-829. |
|71.||Herman A, Weinraub Z, Dreazen E, et al. Combined first trimester nuchal translucency and second Trimester biochemical screening tests among normal pregnancies. Prenat Diagn 2000; 20;781-784. |
|72.||Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynaecol 1999;19:19: 458-62. |
|73.||Brizot ML, Snijders RJM, Butler J, et al. Maternal serum hCG and fetal nuchal translucency thickness for prediction of fetal trisomies in the first trimester of pregnancy. Br J Obstet Gynaecol 1995; 102:127-32. |
|74.||Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on the tests performed during the first and second trimesters. N Engl J Med 1999;341:461-67. |
|75.||De Biasio P, Canini S, Prefumo F, et al. Extent of correlation between first and second trimester markers forDown's syndrome screening. J Med Screen 2000;71-63. |
|76.||Lam YH, Lee CP, Sin SY, et al. First trimester nuchal translucency and second trimester serum screening for Down's syndrome. Ultrasound Obstet Gynecol 1998;12(suppl 1):A62 |
|77.||Azuma M, Yamamoto R, Wakui Y et al. A noval method for the detection of Down syndrome with the use of four serum markers. Am J Obstet Gynecol 2002 Jul;187(1):197-201. |
|78.||Reynolds T, et al. The effect of weight correlation on risk calculation for Down's syndrome. Ann Clin Biochem 1991;28:245-49. |
|79.||Watt HC, Wald NJ. Alternative methods of maternal weight adjustment in maternal serum screening for Down syndrome and NTD. Prenat Diag 1988 Aug; 18(8):842-45. |
|80.||Reynolds T. Practical problems in Down syndrome screening. What should we do about gestation dating? What is the effect of laboratory imprecision? Commun Lab Med 1992; 2;31-38. |
|81.||Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down's syndrome screening. Prenat Diagn 1996;16:1101-1110. |
|82.||Wenstrom KD, Owen J, Boots L, Ethier M. The influence of maternal weight on hCG in the multiple-marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1995 Oct;173 (4): 1297-1300. |
|83.||Spencer K, Ong CYT, Liao AWJ, et al. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status. Prenatal Diagnosis 2000; 20: 852-853. |
|84.||Crossley JA, Aitken DA, Waugh SM et al. Maternal smoking: age distribution, levels of alpha-fetoprotein and human chorionic gonadotropin, and effect on detection of Down syndrome pregnancies in second-trimester screening. Prenat Diagn 2002 Mar; 22(3): 247-55. |
|85.||Spencer K. Ong CYT, Liao AWJ, Nicolaides KH. Influence of parity and gravity on first trimester markers of chromosomal abnormalities. Prenat Diagn 2000 (20), 792-794. |
|86.||Wenstrom KD, Owen J, Boot SL. Effect of parity correlation on Down syndrome detection by the multiple-marker screening test. Am J Obstet Gynecol 1996 Oct;175(4pt 1): 1004-07. |
|87.||Larsen SO et al. Inclusion of serum marker measurements from a previous pregnancy improves Down syndrome screening performance. Prenat diagn 1988 Jul;18(7):706-12. |
|88.||Spencer K, Salonen R, Muller F. Down syndrome screening in multiple pregnancies using AFP and free beta-hcg. Prenat Diagn 1994 Jul;14(7):537-542. |
|89.||Benn PA, Clive JM, Collins R. Medians for second-trimester MSAFP, Hcg and Ue3; differences between races or ethnic groups. Clin Chem 1997 Feb;43 (2): 333-337. |
|90.||Kramer RL, et al. Effect of adjustment of MSAFP levels in insulin-dependent diabetes mellitus. Am J Med Genet 1998 Jan 13;75(2):176-78. |
|91.||Evans MI, Harrison HH, O'Brien JE, et al. Correction for insulin dependent diabetes in maternal serum alpha fetoprotein testing has out lived its usefulness. Am J Obstet Gynecol 2002 Oct;187(4):1084-86. |
|92.||Muller F, Tharabard JC, Ngo S, et al. Positive rates of maternal serum markers for Down Syndrome screening according to maternal age in women over 35 years of age. A study of agreement of eight dedicated software packages. Prenat Diagn 2002 May;22(5):350-53. |
|93.||Muller F, Dreux S, OuryJF, et al. Down syndrome maternal serum marker screening after 18 weeks' gestation. Prenat Diagn 2002 Nov;22(11):1001-04. |
|94.||Bianchi DW, Flint AF, Pizzimenti MF, et al. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Nati Acad Sci USA 1990;87:3279-83. |
|95.||Price JO, Elias S, Wachtel S, Klinger K, et al. Prenatal diagnosis with fetal cells isolated from maternal blood by multiparameter flow cytometry. Am J Obstet Gynecol 1991;165:1731-37. |
|96.||Hamada H, Arinami T, Kubo T et al. Fetal nucleated cells in maternal peripheral blood: Frequency and relationship to gestational age. Hum Genet 1993; 91:427-32. |
|97.||Wachtel S, Elias S, Price J, et al. Fetal cells in the maternal circulation: isolation by multiparameter flow cytometry and confirmation by polymerase chain reaction. Hum Reprod 1991;6:1466-69. |
|98.||Al-Mufti R, Hambley H, Farzaneh F, Nicolaides KH. Investigation of maternal blood enriched for fetal cells:Role in screening and diagnosis of fetal trisomies. Am J Med Genet 1999;85:66-75. |
|99.||Helene A, Elicha G, Sherman E . Culture of fetal cells from maternal blood for prenatal diagnosis. Humen Reproduction Update 2002 (8);6,523-527. |
|100.||LO YMD, Corbetta N, Chamberlain PF, Rai V, et al. Presence of Fetal DNA in Maternal Plasma and Serum. Lancet.1997;350:485- 487. |
|101.||LO YMD, Corbetta N, Chamberlain PF, et al. Fetal DNA in Maternal Plasma: Biology and Diagnostic applications. Clin Chem 46:12;2000;1903-1906. |
|102.||Farina A, LeShane ES, Geralyn M, et al. Eavulation of cell-free fetal DNA as a second trimester maternal serum marker of Down syndrome pregnancy. Clin chem 2003; 49:239-242. |
|103.||Firth HV, Boyd PA, Chamberlain PF, MacKenzie IZ, et al. Severe limb abnormalities after chorion villous sampling at 56-66 days'gestation. Lancet 1991;337:762-763. |
|104.||Firth HV, Boyd PA, Chamberlain PF, et al. Limb defect after chorionic villus sampling. Obstet Gynecol 1995;85:84-88. |
|105.||Olney RS, Khoury MJ, Botto LD, et al. Limb defects and gestational age at chorionic villus sampling [letter].Lancet 1994;344-476. |
|106.||Canadian Collaborative CVS-Amniocentesis Clinical Trial Group. Multicentre randomised clinical trial of chorion villus sampling and amniocentesis. Lancet 1989;i:1-6. |
|107.||Smidt-Jensen S, Permin M, Philip J, et al. Randomised comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 1992;340:1238-44. |
|108.||Ammala P, Hiilesmaa VK, Liukkonen S et al. Randomized trial comparing first trimester transcervical chorionic villus sampling and second trimester amniocentesis. Prenat Diag 1993;13:919-27. |
|109.||European study: MRC working party on the evaluation of chorionic villus sampling. Medical Research Council European trial of chorion villus sampling. Lancet 1991;337 :1491-99. |
|110.||Steele MW, Breg WR. Chromosome analysis of human amniotic-fluid cells. Lancet 1966;I:383-85. |
|111.||Valenti C, Schutta EJ, Kehaty T. Prenatal diagnosis of Down's syndrome. Lancet 1968;ii:220. |
|112.||Tabor A, Madsen M, Obel E, Philip J, et al. Randomised controlled trial of genetic amniocentesis in 4606 low- risk women. Lancet 1986: 1287-93. |
|113.||Byrne DL. Early amniocentesis. Fetal and maternal medicine review 1994;6:203-217. |
|114.||Nilson JP, Alfirevic Z, Golsden C. Early amniocentesis vs chorionic villus sampling. In: pregnancy and childbirh module, Cochrane Database of systemic reviews. Review No 07791,12 may 1994. Publised through "Cochrane updates on disk", Oxford: Update software, 1994, disk1. |
|115.||Campbell TL. Maternal serum alpha-fetoprotein screening : benefits, risks, and costs. J Fam Pract 1987;25:461-467. |
|116.||Cuckle HS, Wald NJ, Linden Baum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;1:926-929. |
|117.||CEMAT Group. Randomized trial to assess safety and fetal outcome of early and mid trimester amniocentesis. Lancet 1998; 351:242-47. |
S-9, Bahwani Singh Road, C-Scheme, Jaipur-302001
Source of Support: None, Conflict of Interest: None
[Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4], [Figure - 5], [Figure - 6], [Figure - 7], [Figure - 8], [Figure - 9], [Figure - 10], [Figure - 11], [Figure - 12], [Figure - 13], [Figure - 14], [Figure - 15], [Figure - 16], [Figure - 17]